Last $2.27 USD
Change Today +0.08 / 3.65%
Volume 905.1K
ATHX On Other Exchanges
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (ATHX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/21/14 - $4.11
52 Week Low
04/28/14 - $1.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ATHERSYS INC (ATHX)

Related News

No related news articles were found.

athersys inc (ATHX) Related Businessweek News

No Related Businessweek News Found

athersys inc (ATHX) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

56 Employees
Last Reported Date: 03/13/14
Founded in 1995

athersys inc (ATHX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $568.8K
President, Chief Operating Officer and Secret...
Total Annual Compensation: $455.4K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $452.9K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $281.3K
Executive Vice President of Regenerative Medi...
Total Annual Compensation: $383.0K
Compensation as of Fiscal Year 2013.

athersys inc (ATHX) Key Developments

Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition

Athersys Limited and the Cell Therapy Catapult announced that Athersys Limited has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, which will support a Phase 2a clinical study evaluating the administration of MultiStem® cell therapy to acute respiratory distress syndrome (ARDS) patients. ARDS is a serious immunological and inflammatory condition characterised by widespread inflammation in the lungs. ARDS can be triggered by pneumonia, sepsis, or other trauma and represents a major cause of morbidity and mortality in the critical care setting. It has significant implications, as it prolongs intensive care unit (ICU) and hospital stays, and requires convalescence in the hospital and rehabilitation. There are limited interventions and no effective drug treatments for ARDS, making it an area of high unmet clinical need with high treatment costs. Given ARDS high treatment costs, a successful cell therapy could be expected to generate significant savings for the healthcare system by reducing days on a ventilator, days in the ICU and total days in the hospital, and importantly, could reduce mortality and improve quality of life for those suffering from the condition. The medical need for a safe and effective treatment of ARDS is significant due to its high mortality rate, and it affects annually approximately 33,000 patients in the UK and 400,000 - 500,000 patients in Europe, the United States and Japan, alone. MultiStem cell therapy has demonstrated the capacity to reduce inflammation, support tissue regeneration and promote homeostasis in acute immunological and injury settings. Preclinical data suggests that MultiStem cells may have a protective effect by shifting the physiological response from pro-inflammatory to anti-inflammatory. In animal models, MultiStem cells have demonstrated an ability to reduce the severity of pulmonary distress, reduce alveolar edema and return lung endothelial permeablity to normal. Intravenous MultiStem treatment early following the onset of the condition may ameliorate the initial hyper-inflammation and reduce the fibrotic activity that follows, thereby speeding the return to and improving the likelihood of more normal lung function, and helping patient recovery.

Athersys, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Athersys, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

Athersys, Inc. Finishes Enrollment of Phase 2 Study of MultiStem(R) Cell Therapy for Ischemic Stroke

Athersys, Inc. announced that it has concluded patient enrollment of its Phase 2 clinical study involving administration of Athersys' MultiStem® cell therapy to ischemic stroke patients. The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects suffering moderate to moderate-severe ischemic strokes. Athersys expects initial results from the study to be disclosed around the end of the first quarter of 2015. An ischemic stroke can be a devastating event for a patient, and effective treatments for stroke are limited, resulting in substantial opportunities for new therapies. Ischemic stroke is caused by a blockage of blood flow to the brain. A leading cause of death and disability globally, each year more than 15 million people are estimated to suffer a stroke, including more than two million people in the United States, Japan and European Union, combined. According to the American Heart Association, ischemic strokes comprise more than 85% of all strokes. Current standard of care for ischemic stroke involves the administration of a thrombolytic (clot dissolving) agent within three to four hours after a stroke has occurred, a narrow window that results in only a small percentage of patients receiving such treatment. In this Phase 2 trial, stroke victims were administered MultiStem cells or placebo intravenously one to two days after the stroke had occurred. If this study shows that MultiStem treatment is both safe and effective following such administration, as was demonstrated in non-clinical studies, the treatment window could be expanded significantly, from hours to days, providing an important new therapeutic option for stroke patients. Based on preclinical studies, Athersys believes that MultiStem treatment has the potential to substantially improve neurological and functional recovery following stroke by attenuating the inflammatory activity that follows the stroke, accelerating the return to immune system homeostasis, supporting protection of at-risk neurons, and by supporting conditions for neuronal recovery and growth, thereby enhancing repair and patient recovery. The MultiStem treatment's potential multidimensional impact distinguishes the cell therapy from other pharmaceutical therapies focused on a single mechanism of benefit. The randomized, double-blind, placebo-controlled Phase 2 clinical trial is being conducted by Athersys at sites in the United States and United Kingdom, and has enrolled subjects who received either MultiStem treatment or placebo one to two days following the stroke. The primary endpoints for the study include safety over the first seven days following treatment and global stroke recovery at day 90, which assesses global disability, neurological deficit and activities of daily living. Additionally, there are multiple secondary and exploratory endpoints evaluating multiple elements of recovery and dysfunction, including biomarkers associated with the condition and recovery, and safety variables over the study period.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $2.27 USD +0.08

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cytori Therapeutics Inc $0.50 USD +0.0024
NeoStem Inc $3.63 USD +0.04
Ocata Therapeutics Inc $6.07 USD +0.01
Pluristem Therapeutics Inc $2.80 USD +0.0899
StemCells Inc $1.07 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 73.4x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 59.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at